China Pharma Holdings Inc. (CPHI)

Overview

China Pharma Holdings, Inc. is a pharmaceutical company based in the People's Republic of China that focuses on the development, manufacturing, and marketing of both generic and branded pharmaceutical and biochemical products. Operating primarily within China, the company caters to hospitals and private retailers, providing a wide range of pharmaceutical solutions in various formats, including dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The firm’s product portfolio aims to address a variety of health issues, from memory decline to hypertension, making significant strides in improving patient care across numerous medical fields.

Products and Services

The company's extensive array of products and services includes:

• Cerebroprotein Hydroloysate injection: Used for treating symptoms of memory decline and attention deficit, showcasing the company’s dedication to neurological health improvement.
• Gastrodin injection: Addresses tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain, illustrating focus on enhancing mental well-being.
• Propylgallate injection: This product is designed for the treatment of cerebral thrombosis, coronary heart disease, and complications post-surgery, highlighting the company’s contribution to cardiovascular disease management.
• Ozagrel Sodium: This medication is aimed at treating acute thrombotic cerebral infarction and dyskinesia, further underlining the commitment to combatting neurological disorders.
• Alginic Sodium Diester injection: Prescribed for ischemic heart, cerebrovascular, and high lipoprotein blood diseases, it emphasizes the company's role in heart and vascular health.
• Bumetanide injection: A solution for edema diseases, it showcases the range of the company’s acute care treatments.
• Candesartan: Targeted at managing hypertension, reinforcing the focus on cardiovascular health.
• Roxithromycin dispersible tablets: For pharyngitis and tonsillitis, extending its reach into infectious diseases.
• Cefaclor dispersible tablets: Addresses tympanitis, lower respiratory tract infections, urinary tract infections, and skin/skin tissue infection, demonstrating versatility in antibacterial treatments.
• Cefalexin capsules: Used for treating acute tonsillitis, emphasizing the concentration on respiratory and throat infections.
• Andrographolide: A treatment for sore throat caused by upper respiratory tract infection, further showcasing the focus on respiratory health.
• Clarithromycin granules and capsules: Yet another tool in the battle against bacterial infections.
• Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets: These provide symptomatic relief for various conditions, highlighting the company’s commitment to pain and symptom management.
• Additional Digestive Disease Treatments: Including Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeprazole, catering to a range of gastrointestinal issues.
• Granisetron Hydrochloride injection: Aimed at treating nausea and vomiting caused by radiotherapy and chemotherapy, underscoring support for cancer patients.
• Noni Enzyme, a food supplement: Reflects the company's venture into nutritional health and wellness.
• Sanitizers and masks: These products represent the company’s response to public health needs, particularly evident in times of health crises.

All these products are made available through a combination of distributors, sales offices, and sales representatives, ensuring widespread access across the People's Republic of China.